Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study

被引：0
|
作者：
Kai Ozaki
Shingo Hatakeyama
Shintaro Narita
Kenichi Hata
Takafumi Yanagisawa
Toshikazu Tanaka
Kyo Togashi
Tomoko Hamaya
Teppei Okamoto
Hayato Yamamoto
Takahiro Yoneyama
Yasuhiro Hashimoto
Takahiro Kimura
Tomonori Habuchi
Chikara Ohyama
机构：
[1] Hirosaki University Graduate School of Medicine,Department of Urology
[2] Akita University School of Medicine,Department of Urology
[3] the Jikei University School of Medicine,Department of Urology
[4] Atsugi City Hospital,Department of Urology
[5] Aomori Prefectural Central Hospital,Department of Urology
[6] Hirosaki University School of Medicine,Department of Advanced Transplant and Regenerative Medicine
来源：
World Journal of Urology | 2023年 / 41卷
关键词：
Hormone-sensitive prostate cancer; Metastasis; Abiraterone; Docetaxel; Cost; Progression-free survival 2;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：67 / 75
页数：8
相关论文
共 50 条
  • [1] Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
    Ozaki, Kai
    Hatakeyama, Shingo
    Narita, Shintaro
    Hata, Kenichi
    Yanagisawa, Takafumi
    Tanaka, Toshikazu
    Togashi, Kyo
    Hamaya, Tomoko
    Okamoto, Teppei
    Yamamoto, Hayato
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Kimura, Takahiro
    Habuchi, Tomonori
    Ohyama, Chikara
    WORLD JOURNAL OF UROLOGY, 2023, 41 (01) : 67 - 75
  • [2] TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis
    Pisano, Chiara
    Turco, Fabio
    Arnaudo, Elena
    Fea, Elena
    Vanella, Paola
    Ruatta, Fiorella
    Filippi, Roberto
    Brusa, Federica
    Prati, Veronica
    Vana, Federica
    Mennitto, Alessia
    Cattrini, Carlo
    Vignani, Francesca
    Dionisio, Rossana
    Icardi, Massimiliano
    Guglielmini, Pamela
    Buosi, Roberta
    Stevani, Ilaria
    Vormola, Roberto
    Numico, Gianmauro
    Depetris, Ilaria
    Comandone, Alessandro
    Gennari, Alessandra
    Rossi, Maura
    Airoldi, Mario
    Vellani, Giorgio
    Ortega, Cinzia
    Tucci, Marcello
    Di Maio, Massimo
    Buttigliero, Consuelo
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 56 - 67.e16
  • [3] A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
    Tsaur, Igor
    Heidegger, Isabel
    Bektic, Jasmin
    Kafka, Mona
    van den Bergh, Roderick C. N.
    Hunting, Jarmo C. B.
    Thomas, Anita
    Brandt, Maximilian P.
    Hoefner, Thomas
    Debedde, Eliott
    Thibault, Constance
    Ermacora, Paola
    Zattoni, Fabio
    Foti, Silvia
    Kretschmer, Alexander
    Ploussard, Guillaume
    Rodler, Severin
    von Amsberg, Gunhild
    Tilki, Derya
    Surcel, Christian
    Rosenzweig, Barak
    Gadot, Moran
    Gandaglia, Giorgio
    Dotzauer, Robert
    CANCER MEDICINE, 2021, 10 (18): : 6354 - 6364
  • [4] Comment on Real-world Efficacy and Toxicity Analysis of Abiraterone Acetate versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer in Asian Patients
    Sudhakaran, Gokul
    CLINICAL GENITOURINARY CANCER, 2024, 22 (05)
  • [5] Efficacy and tolerability of docetaxel chemotherapy in 'real-world' patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Maw, May Tun Hla
    Malik, Laeeq
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 127 - 127
  • [6] Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study
    Okamoto, Teppei
    Noro, Daisuke
    Hatakeyama, Shingo
    Narita, Shintaro
    Mitsuzuka, Koji
    Sakurai, Toshihiko
    Kawamura, Sadafumi
    Hoshi, Senji
    Shimoda, Jiro
    Tanaka, Toshikazu
    Kawaguchi, Toshiaki
    Ishidoya, Shigeto
    Ito, Akihiro
    Tsuchiya, Norihiko
    Habuchi, Tomonori
    Ohyama, Chikara
    BMC CANCER, 2021, 21 (01)
  • [7] Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study
    Teppei Okamoto
    Daisuke Noro
    Shingo Hatakeyama
    Shintaro Narita
    Koji Mitsuzuka
    Toshihiko Sakurai
    Sadafumi Kawamura
    Senji Hoshi
    Jiro Shimoda
    Toshikazu Tanaka
    Toshiaki Kawaguchi
    Shigeto Ishidoya
    Akihiro Ito
    Norihiko Tsuchiya
    Tomonori Habuchi
    Chikara Ohyama
    BMC Cancer, 21
  • [8] Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
    Kelly, R.
    Wong, S. S. L.
    Shapiro, J.
    Weickhardt, A. J.
    Parente, P.
    Azad, A.
    Uccellini, A.
    Torres, J.
    Parnis, F.
    Kwan, E.
    Brown, S.
    Steer, C.
    Warren, M.
    Gibbs, P.
    Anton, A.
    Tran, B.
    ANNALS OF ONCOLOGY, 2022, 33 : S1498 - S1499
  • [9] Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study
    Yanagisawa, Takafumi
    Fukuokaya, Wataru
    Hatakeyama, Shingo
    Narita, Shintaro
    Muramoto, Katsuki
    Katsumi, Kouta
    Takahashi, Hidetsugu
    Urabe, Fumihiko
    Mori, Keiichiro
    Tashiro, Kojiro
    Iwatani, Kosuke
    Shimomura, Tatsuya
    Habuchi, Tomonori
    Kimura, Takahiro
    PROSTATE, 2025, 85 (02): : 165 - 174
  • [10] Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
    Talwar, Harkirat Singh
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (03) : 288 - 290
12345